Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of normal saline (sterile 0.9% sodium chloride solution) and salbutamol (also known as albuterol), typically used for inhalation via nebulizer in the management of acute or severe bronchospasm, especially in asthma and chronic obstructive pulmonary disease (COPD). Salbutamol is a short-acting beta-2 adrenergic receptor agonist that relaxes airway smooth muscle, leading to bronchodilation. Normal saline serves as the diluent to achieve an appropriate nebulization volume for effective delivery of salbutamol to the lungs. This combination is commonly prepared immediately before administration by mixing a specified dose of salbutamol with enough normal saline to reach a total volume suitable for nebulization, usually 3–5 mL[6][8]. The mixture provides rapid relief from bronchospasm and is reserved primarily for severe cases or when metered-dose inhalers are not effective or feasible.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on normal saline + salbutamol.